{"url_path":"/sec/avai/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1740797/0001740797-26-000017-index.html","accession_number":"0001740797-26-000017","cik":"0001740797","ticker":"AVAI","issuer_name":"AVAI BIO, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1740797/0001740797-26-000017-index.html","primary_entity_key":"0001740797","primary_entity_name":"AVAI BIO, INC."},"word_count":817,"has_tables":true,"body_markdown":"false\n2026\nFY\n0001740797\n\n0001740797\n\n2025-04-01\n2026-03-31\n\n0001740797\n\n2026-03-31\n\n0001740797\n\n2026-07-14\n\n0001740797\n\n2025-03-31\n\n0001740797\n\n2024-04-01\n2025-03-31\n\n0001740797\n\nus-gaap:CommonStockMember\n\n2024-03-31\n\n0001740797\n\nus-gaap:PreferredStockMember\n\n2024-03-31\n\n0001740797\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-03-31\n\n0001740797\n\nus-gaap:RetainedEarningsMember\n\n2024-03-31\n\n0001740797\n\n2024-03-31\n\n0001740797\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001740797\n\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001740797\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001740797\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001740797\n\nus-gaap:CommonStockMember\n\n2024-04-01\n2025-03-31\n\n0001740797\n\nus-gaap:PreferredStockMember\n\n2024-04-01\n2025-03-31\n\n0001740797\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-04-01\n2025-03-31\n\n0001740797\n\nus-gaap:RetainedEarningsMember\n\n2024-04-01\n2025-03-31\n\n0001740797\n\nus-gaap:CommonStockMember\n\n2025-04-01\n2026-03-31\n\n0001740797\n\nus-gaap:PreferredStockMember\n\n2025-04-01\n2026-03-31\n\n0001740797\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-04-01\n2026-03-31\n\n0001740797\n\nus-gaap:RetainedEarningsMember\n\n2025-04-01\n2026-03-31\n\n0001740797\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001740797\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001740797\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001740797\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001740797\n\n2025-03-24\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n**FORM 10-K**\n\n** **\n\n**[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR\n15(D) OF THE SECURITIES**\n\n**EXCHANGE ACT OF 1934**\n\nFor the fiscal year ended March 31, 2026\n\n \n\n**[ ] TRANSITION REPORT PURSUANT TO SECTION\n13 OR 15(D) OF THE**\n\n**SECURITIES EXCHANGE ACT OF 1934**\n\nFor the transition period from __________ to __________\n\n \n\nCommission file number 333-225433\n\n** **\n\n**AVAI BIO, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**AVANT TECHNOLOGIES INC.**\n\n(Former name or former address, if changed since last report)\n\n \n\n**Nevada**\n**38-4053064**\n \n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n \n \n\n**Sv. Stepono g. 27D-2, LT-01315\nVilnius, Lithuania**\n\n**(**USA Address: 5348\nVegas Drive, Las Vegas, NV, 89108)\n\n(Address of principal executive\noffices and Zip Code)\n\n \n\nRegistrant’s telephone number, including area\ncode: **866****-533-0065**\n\nRegistrant’s email:info@avanttechnologies.com\n\n \n\nSecurities registered under Section 12(b) of the Exchange Act:\n\n \n\nTitle of each class\n \nTrading Symbol(s)\n \nName of each exchange on which registered\n\n**Common Stock, $0.001 par value**\n \n**AVAI**\n \n**OTC Markets**\n\n \n \n \n \n \n\nSecurities registered under Section 12(g) of the Exchange Act:\n\n**None**\n\n \n\nIndicate by check mark if the registrant is a well-known\nseasoned issuer, as defined in Rule 405 of the Securities Act.\n\nYes [ ]        No [X]\n\n \n\nIndicate by check mark if the registrant is not required\nto file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.\n\nYes [ ]        No [X]\n\n \n\nIndicate by check mark whether the registrant (1) has\nfiled all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days.\n\nYes [X]        No [ ]\n\n \n\nIndicate by check mark whether the registrant has\nsubmitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of\nthis chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\n\nYes [X]        No [ ]\n\n \n\n  smaller reporting company. See the definitions\nof “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging\ngrowth company” in Rule 12b-2 of the Exchange Act:\n\n \n\n \n \n \n \n\nLarge accelerated filer\n[ ]\nAccelerated filer\n[ ]\n\nNon-accelerated filer\n[X]\nSmaller reporting company\n[X]\n\n(Do not check if a smaller reporting company)\nEmerging growth company\n[ ]\n\n \n\nIf an emerging growth company, indicate by check mark\nif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 7(a)(2)(B) of the Securities Act.\n\n[ ]\n\n \n\nIndicate by check mark whether the registrant has\nfiled a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting\nunder Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its\naudit report.\n\n[ ]\n\n \n\nIf securities are registered pursuant to Section 12(b)\nof the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of\nan error to previously issued financial statements.\n\n[ ]\n\n \n\nIndicate by check mark whether any of those error\ncorrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive\nofficers during the relevant recovery period pursuant to §240.10D-1(b).\n\n[ ]\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined\nin Rule 12b-2 of the Exchange Act).\n\nYes [ ]        No [X]\n\n \n\nAs of March 31, 2026, the market value of our common\nstock held by non-affiliates was approximately $36,848,619 which is computed based upon the closing price on that date of the Common\nStock of the registrant on the OTC QB maintained by OTC Markets Group Inc. of $0.32. For purposes of this response, the registrant has\nassumed that its directors, executive officers and beneficial owners of 5% or more of its Common Stock are deemed affiliates of the registrant.\n\n \n\nState the number of shares outstanding of each of\nthe issuer's classes of common equity, as of the latest practicable date: 153,916,565\ncommon shares issued and outstanding as of July 14, 2026.\n\n \n\nDocuments incorporated by reference: None\n\n \n\n \n\n \n\nTABLE OF CONTENTS\n\n \n\n \n \n \n\n \n \n**Page**\n\n \n \n \n\n**PART I**"}